4//SEC Filing
Simon Farrell 4
Accession 0000950170-25-080885
CIK 0001563880other
Filed
Jun 2, 8:00 PM ET
Accepted
Jun 3, 4:00 PM ET
Size
6.2 KB
Accession
0000950170-25-080885
Insider Transaction Report
Form 4
Simon Farrell
Chief Commercial Officer
Transactions
- Award
Performance Stock Option (right to buy)
2025-05-31+72,000→ 110,400 totalExercise: $2.38From: 2025-05-31Exp: 2034-02-14→ Common Stock (72,000 underlying)
Footnotes (1)
- [F1]Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 120,000 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 38,400 shares of common stock. On May 31, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the CORAL trial were satisfied, resulting in the vesting of the option as to 72,000 shares of common stock.
Documents
Issuer
Trevi Therapeutics, Inc.
CIK 0001563880
Entity typeother
Related Parties
1- filerCIK 0001965585
Filing Metadata
- Form type
- 4
- Filed
- Jun 2, 8:00 PM ET
- Accepted
- Jun 3, 4:00 PM ET
- Size
- 6.2 KB